Summit Investment Advisors Inc. Sells 155 Shares of Agilent Technologies, Inc. (NYSE:A)

Summit Investment Advisors Inc. lowered its position in shares of Agilent Technologies, Inc. (NYSE:A) by 5.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,800 shares of the medical research company’s stock after selling 155 shares during the period. Summit Investment Advisors Inc.’s holdings in Agilent Technologies were worth $376,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of A. Sienna Gestion increased its holdings in Agilent Technologies by 29.8% during the 4th quarter. Sienna Gestion now owns 78,445 shares of the medical research company’s stock valued at $10,537,000 after purchasing an additional 17,991 shares during the period. Sequoia Financial Advisors LLC boosted its holdings in Agilent Technologies by 8.5% in the fourth quarter. Sequoia Financial Advisors LLC now owns 33,898 shares of the medical research company’s stock valued at $4,554,000 after acquiring an additional 2,664 shares in the last quarter. S.E.E.D. Planning Group LLC raised its holdings in Agilent Technologies by 12.7% in the 4th quarter. S.E.E.D. Planning Group LLC now owns 42,587 shares of the medical research company’s stock worth $5,721,000 after purchasing an additional 4,805 shares in the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Agilent Technologies by 9.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 43,862 shares of the medical research company’s stock valued at $5,892,000 after purchasing an additional 3,915 shares in the last quarter. Finally, Daiwa Securities Group Inc. increased its position in shares of Agilent Technologies by 16.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 49,288 shares of the medical research company’s stock valued at $6,621,000 after buying an additional 6,802 shares during the period. Hedge funds and other institutional investors own 87.42% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on A. Barclays reduced their target price on Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th. TD Cowen upped their target price on shares of Agilent Technologies to $135.00 and gave the stock a “buy” rating in a research report on Thursday, April 10th. Wells Fargo & Company lowered their price target on shares of Agilent Technologies from $155.00 to $135.00 and set an “overweight” rating for the company in a research report on Thursday. Robert W. Baird cut their price objective on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. Finally, StockNews.com upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Agilent Technologies has a consensus rating of “Moderate Buy” and an average target price of $144.58.

Agilent Technologies Stock Down 0.3 %

A stock opened at $102.38 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $155.35. The stock has a market capitalization of $29.19 billion, a P/E ratio of 23.54, a P/E/G ratio of 2.89 and a beta of 1.19. The business has a fifty day moving average price of $119.55 and a 200-day moving average price of $132.40.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. The business had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. Equities analysts forecast that Agilent Technologies, Inc. will post 5.54 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be given a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.76%.

Insider Buying and Selling at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,911 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the sale, the chief executive officer now owns 39,652 shares of the company’s stock, valued at $5,947,800. This represents a 4.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Rodney Gonsalves sold 1,908 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $121.98, for a total transaction of $232,737.84. Following the completion of the transaction, the vice president now directly owns 21,786 shares in the company, valued at approximately $2,657,456.28. The trade was a 8.05 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,638 shares of company stock worth $731,229. Insiders own 0.26% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.